Sanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
Follow SNY
Alert me
Sanofi (SNY) P/B ratio
As of 5 November 2026, Sanofi (SNY) trades at a P/B ratio of 1.4×. Over the past ten years it has ranged from 1.2× (October 2026) to 2.3× (August 2015); the current reading is higher than 7% of that period. That is below the Drug Manufacturers General industry median of 5.2× and below the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 1.5× | 1.75% |
| FY2024 | 1.4× | (7.88%) |
| FY2023 | 1.6× | 0.38% |
| FY2022 | 1.5× | (4.06%) |
| FY2021 | 1.6× | 2.15% |
| FY2020 | 1.6× | (16.67%) |
| FY2019 | 1.9× | 18.03% |
| FY2018 | 1.6× | (2.79%) |
| FY2017 | 1.7× | 0.08% |
| FY2016 | 1.7× | (6.81%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 1.2× | (3.07%) |
| Jun 2026 | 1.3× | (11.75%) |
| Mar 2026 | 1.4× | (1.90%) |
| Dec 2025 | 1.5× | 1.15% |
| 39 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| SNY Sanofi | 1.4× |
| PFE Pfizer Inc. compare | 1.9× |
| GSK GSK PLC Sponsored ADR compare | 4.1× |
| NVO Novo Nordisk A/S compare | 5.2× |
| BMY Bristol Myers Squibb Company compare | 5.5× |
| AZN AstraZeneca PLC compare | 5.6× |
| NVS Novartis AG compare | 8.2× |
| GILD Gilead Sciences, Inc. compare | 16.1× |
| AMGN Amgen Inc. compare | 21.4× |
| Drug Manufacturers General industry median | 5.2× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on SNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement